A 68930 hydrochloride
Potent and selective D1-like dopamine receptor agonist (EC50 values are 2.1 and 3910 nM for D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 307.78. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.25 mL||16.25 mL||32.49 mL|
|5 mM||0.65 mL||3.25 mL||6.5 mL|
|10 mM||0.32 mL||1.62 mL||3.25 mL|
|50 mM||0.06 mL||0.32 mL||0.65 mL|
References are publications that support the products' biological activity.
Deveney and Waddingto (1997) Psychopharmacological distinction between novel full-efficacy "D1-like" dopamine receptor agonists. Pharmacol.Biochem.Behav. 58 551 PMID: 9300618
Kebabian et al (1990) A68930: a potent and specific agonist for the D-1 dopamine receptor. Am.J.Hypertens. 3 40S PMID: 2143387
Quaglia et al (1990) (1R,3S)-1-(Aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J.Med.Chem. 33 2948 PMID: 1977907
If you know of a relevant reference for A 68930 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: A 68930 hydrochloride, supplier, Potent, selective, D1-like, agonists, Dopamine, D1, Receptors, D5, dopaminergic, A68930, hydrochloride, D1, and, D5, Receptors, D1, and, D5, Receptors, Tocris Bioscience
3 Citations for A 68930 hydrochloride
Citations are publications that use Tocris products. Selected citations for A 68930 hydrochloride include:
Mizuta et al (2013) The dopamine D1 receptor is expressed and facilitates relaxation in airway smooth muscle. PLoS One 14 89 PMID: 24004608
Guha et al (2012) Stimulation of the D5 dopamine receptor acidifies the lysosomal pH of retinal pigmented epithelial cells and decreases accumulation of autofluorescent photoreceptor debris. J Neurochem 122 823 PMID: 22639870
Blasic et al (2012) Phosphorylation of mouse melanopsin by protein kinase A. Sci Rep 7 e45387 PMID: 23049792
Do you know of a great paper that uses A 68930 hydrochloride from Tocris? If so please let us know.
Reviews for A 68930 hydrochloride
There are currently no reviews for this product. Be the first to review A 68930 hydrochloride and earn rewards!
Have you used A 68930 hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.